Article

Transscleral drug delivery system under development

Fort Lauderdale, FL-Efforts to develop an episcleral anecortave acetate transscleral drug delivery system (AA-TSDDD), targeted for patients with age-related macular degeneration (AMD), are progressing initially in the rhesus monkey as preliminary devices are being redesigned to decrease postoperative problems, said Timothy W. Olsen, MD.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
© 2024 MJH Life Sciences

All rights reserved.